Entasis Therapeutics Holdings Inc.

2.2000.00Vol 109.71K1Y Perf -20.58%
Jun 24th, 2022 16:00 DELAYED
BID2.18 ASK2.20
Open2.18 Previous Close2.20
Pre-Market- After-Market2.18
 - -  -0.02 -0.91%
Target Price
3.25 
Analyst Rating
Moderate Buy 2.50
Potential %
47.73 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
     32.87
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
32.26 
Earnings Rating
Strong Sell
Market Cap105.27M 
Earnings Date
10th Aug 2022
Alpha-0.03 Standard Deviation0.19
Beta1.44 

Today's Price Range

2.182.20

52W Range

1.403.88

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.46%
1 Month
0.46%
3 Months
15.79%
6 Months
-5.58%
1 Year
-20.58%
3 Years
-64.34%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ETTX2.200.00000.00
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.20-0.32-60.00
Q04 2021-0.26-0.253.85
Q03 2021-0.26-0.260.00
Q02 2021-0.24-0.29-20.83
Q01 2021-0.34-0.2914.71
Q04 2020-0.37-0.1267.57
Q03 2020-0.51-0.3727.45
Q02 2020-0.58-0.78-34.48
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.28-27.27Negative
9/2022 QR-0.31-34.78Negative
12/2022 FY-1.20-25.00Negative
12/2023 FY-1.15-64.29Negative
Next Report Date10th Aug 2022
Estimated EPS Next Report-0.28
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume109.71K
Shares Outstanding47.85K
Shares Float18.61M
Trades Count165
Dollar Volume240.41K
Avg. Volume175.03K
Avg. Weekly Volume81.77K
Avg. Monthly Volume230.12K
Avg. Quarterly Volume213.21K

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) stock closed at 2.2 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 109.71K shares and market capitalization of 105.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Entasis Therapeutics Holdings Inc. CEO is Manoussos Perros.

The one-year performance of Entasis Therapeutics Holdings Inc. stock is -20.58%, while year-to-date (YTD) performance is 0.46%. ETTX stock has a five-year performance of %. Its 52-week range is between 1.4 and 3.8799, which gives ETTX stock a 52-week price range ratio of 32.26%

Entasis Therapeutics Holdings Inc. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 6.30, a price-to-sale (PS) ratio of 11.40, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -106.70%, a ROC of -127.80% and a ROE of -169.78%. The company’s profit margin is -%, its EBITDA margin is -660.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Entasis Therapeutics Holdings Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Entasis Therapeutics Holdings Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Entasis Therapeutics Holdings Inc. is Moderate Buy (2.5), with a target price of $3.25, which is +47.73% compared to the current price. The earnings rating for Entasis Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Entasis Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Entasis Therapeutics Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 26.47, ATR14 : 0.03, CCI20 : 172.47, Chaikin Money Flow : -0.03, MACD : 0.06, Money Flow Index : 51.80, ROC : 0.92, RSI : 70.91, STOCH (14,3) : 100.00, STOCH RSI : 0.91, UO : 62.42, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Entasis Therapeutics Holdings Inc. in the last 12-months were: David Altarac (Sold 3 759 shares of value $11 991 ), Elizabeth M. Keiley (Sold 3 759 shares of value $11 991 ), John Mueller (Sold 4 001 shares of value $12 763 ), Manoussos Perros (Sold 35 922 shares of value $114 591 ), Matthew Ronsheim (Sold 3 759 shares of value $11 991 ), Michael Gutch (Sold 3 759 shares of value $11 991 ), Ruben Tommasi (Sold 3 759 shares of value $11 991 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (25.00 %)
1 (25.00 %)
2 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (75.00 %)
3 (75.00 %)
2 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.50
Moderate Buy
2.50
Moderate Buy
2.00

Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its products candidate includes Zoliflodacin, ETX0282CPDP, and NBP program.

CEO: Manoussos Perros

Telephone: +1 781 810-0120

Address: 35 Gatehouse Drive, Waltham 02451, MA, US

Number of employees: 47

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

51%49%

Bearish Bullish

54%46%

TipRanks News for ETTX

Wed, 27 Apr 2022 10:16 GMT Entasis Therapeutics Holdings (ETTX) Gets a Hold Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Tue, 08 Mar 2022 12:32 GMT Wedbush Downgrades Entasis Therapeutics Holdings (ETTX) to Hold

- TipRanks. All rights reserved.

News

Stocktwits